Prionab

Headquarters: Cambridge, Massachusetts, USA Founded: 2018 Focus: Prion diseases, neurodegenerative disorders, anti-prion therapeutics Website: [prionab.com](https://www.prionab.com)

Overview

Prionab is a biotechnology company dedicated to developing disease-modifying therapies for prion diseases and related neurodegenerative disorders. The company targets the pathological misfolding of the prion protein (PrP^Sc), which is the causative agent of fatal transmissible spongiform encephalopathies (TSEs)[@prusiner2024].

Based in the biotechnology hub of Cambridge, Massachusetts, Prionab leverages cutting-edge research in protein misfolding, molecular chaperones, and immunotherapeutic approaches to address these invariably fatal neurological conditions. The company's mission is to transform prion diseases from universally fatal diagnoses into manageable, treatable conditions.

Company Background and History

Prionab was founded in 2018 by a team of neuroscientists and protein biochemists who recognized the urgent unmet need for effective prion disease therapeutics. The founding team brought together decades of combined experience in prion biology, drug discovery, and clinical neurology.

Headquarters: Cambridge, Massachusetts, USA Founded: 2018 Focus: Prion diseases, neurodegenerative disorders, anti-prion therapeutics Website: [prionab.com](https://www.prionab.com)

Overview

Prionab is a biotechnology company dedicated to developing disease-modifying therapies for prion diseases and related neurodegenerative disorders. The company targets the pathological misfolding of the prion protein (PrP^Sc), which is the causative agent of fatal transmissible spongiform encephalopathies (TSEs)[@prusiner2024].

Based in the biotechnology hub of Cambridge, Massachusetts, Prionab leverages cutting-edge research in protein misfolding, molecular chaperones, and immunotherapeutic approaches to address these invariably fatal neurological conditions. The company's mission is to transform prion diseases from universally fatal diagnoses into manageable, treatable conditions.

Company Background and History

Prionab was founded in 2018 by a team of neuroscientists and protein biochemists who recognized the urgent unmet need for effective prion disease therapeutics. The founding team brought together decades of combined experience in prion biology, drug discovery, and clinical neurology.

Cambridge, Massachusetts, provides Prionab with access to world-class research institutions including MIT, Harvard, and leading hospitals such as Massachusetts General Hospital and Brigham and Women's Hospital. This ecosystem has facilitated collaborations with academic researchers and access to cutting-edge technologies for studying protein misfolding diseases.

The company has operated as a privately held biotechnology firm, receiving funding through a combination of private investment, NIH grants focused on rare disease research, and strategic partnerships with academic institutions specializing in neurodegenerative disease research.

Science and Technology

Prion Disease Biology

Prion diseases represent a unique category of neurodegenerative disorders caused by the misfolding of the cellular prion protein (PrP^C) into the pathogenic scrapie isoform (PrP^Sc). This misfolded protein exhibits remarkable templating properties, able to convert normal prion proteins into the disease-causing form through a seeded polymerization mechanism[@prusiner2024].

The pathological cascade in prion diseases includes:

• Protein aggregation: Formation of amyloid fibrils and oligomers in the brain parenchyma
• Neuronal loss: Progressive neurodegeneration affecting multiple brain regions
• Spongiform changes: Characteristic vacuolation of brain tissue visible on histology
• Microglial activation: Inflammatory responses contributing to neuronal damage
• Neurotransmitter depletion: Loss of synaptic function and connectivity

Therapeutic Approaches

Prionab pursues multiple therapeutic modalities to address prion diseases:

Pipeline and Programs

| Program | Approach | Indication | Development Stage |
|---------|----------|------------|-------------------|
| PRN-001 | Anti-prion antibody | Creutzfeldt-Jakob Disease (CJD) | Preclinical |
| PRN-002 | Small molecule | Creutzfeldt-Jakob Disease | Discovery |
| PRN-003 | Gene therapy approach | Fatal Familial Insomnia | Research |
| PRN-004 | Combination therapy | Prion disease prevention | Early research |

PRN-001: Anti-Prion Antibody

PRN-001 represents Prionab's lead therapeutic candidate, a monoclonal antibody designed to bind specifically to the pathological PrP^Sc isoform while sparing the normal cellular prion protein. This selectivity is crucial, as the normal prion protein serves important physiological functions in neuronal maintenance and synaptic plasticity.

The antibody is designed to:

• Neutralize circulating PrP^Sc oligomers
• Flag pathological proteins for immune clearance
• Cross the [blood-brain barrier](/entities/blood-brain-barrier) for direct CNS activity
• Maintain long serum half-life for sustained therapeutic effect

PRN-002: Small Molecule Inhibitor

The PRN-002 program focuses on identifying small molecules that can stabilize the native conformation of the prion protein or prevent the structural transition to PrP^Sc. This approach offers potential advantages including oral bioavailability and better distribution throughout the body.

PRN-003: Gene Therapy

Prionab's gene therapy program explores AAV-delivered approaches to modify prion protein expression in the central nervous system. While still in early research stages, this modality could provide long-lasting therapeutic benefit through single administration.

Clinical Indications

Human Prion Diseases

Prionab's pipeline addresses several fatal human prion diseases:

Creutzfeldt-Jakob Disease (CJD)

• Sporadic CJD: Accounts for ~85% of human prion disease cases
• Genetic CJD: Associated with mutations in the PRNP gene
• Iatrogenic CJD: Acquired through contaminated surgical materials or growth hormone
• Variant CJD: Linked to bovine spongiform encephalopathy (BSE) exposure

• Rare genetic prion disease caused by PRNP mutations
• Characterized by progressive insomnia and autonomic dysfunction
• Typically manifests in middle age

• Rare autosomal dominant genetic prion disease
• Progressive cerebellar ataxia and dementia
• Longer disease duration than CJD

Related Neurodegenerative Conditions

Prionab's research has implications for more common neurodegenerative diseases sharing protein misfolding pathology:

• [Alzheimer's disease](/diseases/alzheimers-disease): [Amyloid-beta](/proteins/amyloid-beta) and [tau protein](/proteins/tau) misfolding
• [Parkinson's disease](/diseases/parkinsons-disease): [Alpha-synuclein](/proteins/alpha-synuclein) aggregation
• Amyotrophic lateral sclerosis (ALS): [TDP-43 protein](/mechanisms/tdp-43-proteinopathy) misfolding

Research Collaborations

Prionab maintains active collaborations with:

• Academic prion research centers at major universities
• NIH-funded rare disease research consortia
• [Pharmaceutical](/companies) partners interested in neurodegeneration
• Patient advocacy groups for prion diseases

Recent Developments and Future Directions

The field of prion disease therapeutics has seen increased activity in recent years, with growing recognition of the need for disease-modifying treatments. Prionab continues to advance its pipeline through:

• IND-enabling studies for PRN-001
• Ongoing discovery efforts for next-generation compounds
• Expansion of scientific understanding of prion propagation mechanisms
• Engagement with regulatory agencies on clinical trial design for rare diseases

See Also

• [Prion Diseases](/diseases/prion-diseases)
• [Creutzfeldt-Jakob Disease](/diseases/creutzfeldt-jakob-disease)
• [Protein Misfolding in Neurodegeneration](/mechanisms/protein-misfolding-neurodegeneration)
• [Neurodegeneration](/diseases/neurodegeneration)
• [Autophagy](/mechanisms/autophagy)
• [Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Prionab discovered through SciDEX knowledge graph analysis: